Hirsutism causes: Difference between revisions
Ochuko Ajari (talk | contribs) |
Jose Loyola (talk | contribs) |
||
(14 intermediate revisions by 3 users not shown) | |||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The cause of hirsutism can be either an increased level of [[androgen]]s (male [[hormone]]s) or an oversensitivity of [[hair follicles]] to androgens. Male hormones such as [[testosterone]] stimulate hair growth, increase size and intensify the pigmentation of hair. Other symptoms associated with a high level of male hormones include [[Acne vulgaris|acne]] and deepening of the voice and increased muscle mass. Growing evidence implicates high circulating levels of insulin in women to the development of hirsutism. This theory is consistent with the observation that obese (and thus presumably insulin resistant hyperinsulinemic) women are at high risk of becoming hirsute. Further, treatments that lower insulin levels will lead to a reduction in hirsutism. | The cause of hirsutism can be either an increased level of [[androgen]]s (male [[hormone]]s) or an oversensitivity of [[hair follicles]] to androgens, and the most common cause is [[polycystic ovary syndrome]]. Male hormones such as [[testosterone]] stimulate hair growth, increase size and intensify the pigmentation of hair. Other symptoms associated with a high level of male hormones include [[Acne vulgaris|acne]] and deepening of the voice and increased muscle mass. Growing evidence implicates high circulating levels of insulin in women to the development of hirsutism. This theory is consistent with the observation that obese (and thus presumably insulin resistant hyperinsulinemic) women are at high risk of becoming hirsute. Further, treatments that lower insulin levels will lead to a reduction in hirsutism. | ||
==Causes== | ==Causes== | ||
===Life Threatening Causes=== | ===Life Threatening Causes=== | ||
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. | Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. | ||
*There are no known life threatening causes of hirsutism. | |||
===Common Causes=== | ===Common Causes=== | ||
*[[tumor|Androgen secreting tumors]] <ref name="pmid20198556">{{cite journal| author=Klotz RK, Müller-Holzner E, Fessler S, Reimer DU, Zervomanolakis I, Seeber B et al.| title=Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature. | journal=Exp Clin Endocrinol Diabetes | year= 2010 | volume= 118 | issue= 5 | pages= 291-7 | pmid=20198556 | doi=10.1055/s-0029-1225351 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20198556 }} </ref> | |||
*[[Congenital adrenal hyperplasia]] | *[[Congenital adrenal hyperplasia]] | ||
*[[Cushing's syndrome]] | *[[Cushing's syndrome]] | ||
*[[hirsutism|Idiopathic hirsutism]] | *[[hirsutism|Idiopathic hirsutism]] | ||
*[[Polycystic ovary syndrome]] <ref name="pmid14764747">{{cite journal |vauthors=Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR |title=Androgen excess in women: experience with over 1000 consecutive patients |journal=J. Clin. Endocrinol. Metab. |volume=89 |issue=2 |pages=453–62 |year=2004 |pmid=14764747 |doi=10.1210/jc.2003-031122 |url=}}</ref> | |||
*[[Polycystic ovary syndrome | |||
===Causes by Organ System=== | ===Causes by Organ System=== | ||
Line 21: | Line 22: | ||
{| style="width:80%; height:100px" border="1" | {| style="width:80%; height:100px" border="1" | ||
| style="width:25%" bgcolor="LightSteelBlue" ; border="1" |'''Cardiovascular''' | | style="width:25%" bgcolor="LightSteelBlue" ; border="1" |'''Cardiovascular''' | ||
| style="width:75%" bgcolor="Beige" ; border="1" | | | style="width:75%" bgcolor="Beige" ; border="1" | [[Insulin resistance syndrome]] | ||
|- | |- | ||
| bgcolor="LightSteelBlue" | '''Chemical/Poisoning''' | | bgcolor="LightSteelBlue" | '''Chemical/Poisoning''' | ||
Line 32: | Line 33: | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
| '''Dermatologic''' | | '''Dermatologic''' | ||
| bgcolor="Beige" | | | bgcolor="Beige" | [[Dermatomyositis]] | ||
|- | |- | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
| '''Drug Side Effect''' | | '''Drug Side Effect''' | ||
| bgcolor="Beige" | | | bgcolor="Beige" |[[Aripiprazole]], [[bimatoprost]], [[bupropion]], [[carbamazepine]], [[clonazepam]], [[corticosteroids]], [[cyclosporine]], [[danazol]], [[dantrolene]], [[desogestrel and ethinyl estradiol]], [[dexamethasone]], [[diazoxide]], [[donepezil]], [[estrogens]], [[eszopiclone]], [[ethosuximide]], [[ethotoin]], [[ethynodiol diacetate and ethinyl estradiol]], [[fluoxetine]], [[fluoxymesterone]], [[gestrinone]], [[pegylated interferon alfa-2a|interferon alfa]], [[isotretinoin]], [[lamotrigine]], [[leuprolide]], [[methyltestosterone]], [[mycophenolate]], [[olanzapine]], [[oxandrolone]], [[oxymetholone]], [[paroxetine]], [[phenytoin]], [[prednisolone]], [[pregabalin]], [[progestin]], [[selegiline]], [[tacrolimus]], [[testosterone]], [[tiagabine]], [[trazodone]], [[valproic acid]], [[vasodilators]], [[venlafaxine]], [[zonisamide]] | ||
|- | |- | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
Line 58: | Line 45: | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
| '''Endocrine''' | | '''Endocrine''' | ||
| bgcolor="Beige" | | | bgcolor="Beige" |[[Acromegaly]], [[adrenal adenoma]], [[adrenal carcinoma]], [[adrenal tumor]], [[arrhenoblastoma]], [[congenital adrenal hyperplasia]], [[Cushing syndrome]], [[Cushing's disease]], [[hyperprolactinemia]], [[hypothyroidism]], [[insulin resistance syndrome]], [[luteoma]], [[pituitary tumor]], [[polycystic ovary syndrome]], [[porphyria cutanea tarda]], [[Stein-Leventhal syndrome]], [[testosterone]] | ||
|- | |- | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
Line 76: | Line 57: | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
| '''Genetic''' | | '''Genetic''' | ||
| bgcolor="Beige" | | | bgcolor="Beige" |[[11β-hydroxylase deficiency]], [[21-hydroxylase deficiency]], [[Achard-Thiers syndrome]], [[alpha-L-iduronidase deficiency]], [[Ambras syndrome]], [[Coffin-Siris syndrome]], [[congenital adrenal hyperplasia]], [[Cornelia de Lange Syndrome]], [[Hurler syndrome]], [[hypertrichosis lanuginosa]], [[Miller-Dieker syndrome]], [[nodulosis-arthropathy-osteolysis syndrome]], [[Turner syndrome]] | ||
|- | |- | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
Line 101: | Line 81: | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
| '''Nutritional/Metabolic''' | | '''Nutritional/Metabolic''' | ||
| bgcolor="Beige" | | | bgcolor="Beige" | [[Alpha-L-iduronidase deficiency]], [[cortisone reductase deficiency]], [[Hurler syndrome]], [[i-cell disease]], [[porphyria cutanea tarda]] | ||
|- | |- | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
| '''Obstetric/Gynecologic''' | | '''Obstetric/Gynecologic''' | ||
| bgcolor="Beige" | | | bgcolor="Beige" |[[Ovarian cancer]], ovarian hyperthecosis, [[ovarian tumor]], [[polycystic ovary syndrome]], [[Stein-Leventhal syndrome]] | ||
|- | |- | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
| '''Oncologic''' | | '''Oncologic''' | ||
| bgcolor="Beige" | | | bgcolor="Beige" | [[Adrenal adenoma]], [[adrenal carcinoma]], [[adrenal tumor]], [[arrhenoblastoma]], [[luteoma]], [[ovarian cancer]], [[ovarian tumor]], [[pituitary tumor]], [[testicular tumor]] | ||
|- | |- | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
Line 135: | Line 113: | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
| '''Rheumatology/Immunology/Allergy''' | | '''Rheumatology/Immunology/Allergy''' | ||
| bgcolor="Beige" | | | bgcolor="Beige" | [[Dermatomyositis]], [[insulin resistance syndrome]] | ||
|- | |- | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
| '''Sexual''' | | '''Sexual''' | ||
| bgcolor="Beige" | | | bgcolor="Beige" | [[Ovarian cancer]], ovarian hyperthecosis, [[ovarian tumor]], [[polycystic ovary syndrome]] | ||
|- | |- | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
Line 151: | Line 129: | ||
|- bgcolor="LightSteelBlue" | |- bgcolor="LightSteelBlue" | ||
| '''Miscellaneous''' | | '''Miscellaneous''' | ||
| bgcolor="Beige" | | | bgcolor="Beige" | [[hirsutism|Idiopathic hirsutism]] | ||
|- | |- | ||
|} | |} | ||
===Causes in Alphabetical Order=== | ===Causes in Alphabetical Order=== | ||
{{columns-list| | |||
*[[11β-hydroxylase deficiency]] | |||
*[[21-hydroxylase deficiency]] | |||
*[[Achard-Thiers syndrome]] | |||
{{columns-list| | *[[Acromegaly]] | ||
* [[Adrenal | *[[Adrenal adenoma]] | ||
* [[ | *[[Adrenal carcinoma]] | ||
* [[Cushing's disease]] | *[[Adrenal tumor]] | ||
* [[Desogestrel and | *[[Alpha-L-iduronidase deficiency]] | ||
* [[Dexamethasone]] | *[[Ambras syndrome]] | ||
* [[Ethosuximide]] | *[[Aripiprazole]] | ||
* [[Ethynodiol diacetate and ethinyl estradiol]] | *[[Arrhenoblastoma]] | ||
* [[Fluoxymesterone]] | *[[Bimatoprost]] | ||
* [[ | *[[Bupropion]] | ||
* [[ | *[[Carbamazepine]] | ||
* [[ | *[[Clonazepam]] | ||
* [[Insulin resistance]] | *[[Coffin-Siris syndrome]] | ||
* [[Methyltestosterone]] | *[[Congenital adrenal hyperplasia]] | ||
* [[Ovarian tumor]] | *[[Cornelia de Lange Syndrome]] | ||
* [[Oxandrolone]] | *[[Corticosteroids]] | ||
* [[Oxymetholone]] | *[[Cortisone reductase deficiency]] | ||
* [[Prednisolone]] | *[[Cushing syndrome]] | ||
* [[Tiagabine]] | *[[Cushing's disease]] | ||
*[[Cyclosporine]] | |||
*[[Danazol]] | |||
*[[Dantrolene]] | |||
*[[Dermatomyositis]] | |||
*[[Desogestrel and ethinyl estradiol]] | |||
*[[Dexamethasone]] | |||
*[[Diazoxide]] | |||
*[[Donepezil]] | |||
*[[Estrogens]] | |||
*[[Eszopiclone]] | |||
*[[Ethosuximide]] | |||
*[[Ethotoin]] | |||
*[[Ethynodiol diacetate and ethinyl estradiol]] | |||
*[[Fluoxetine]] | |||
*[[Fluoxymesterone]] | |||
*[[Gestrinone]] | |||
*[[Hurler syndrome]] | |||
*[[Hyperprolactinemia]] | |||
*[[Hypertrichosis lanuginosa]] | |||
*[[Hypothyroidism]] | |||
*[[I-cell disease]] | |||
*[[hirsutism|Idiopathic hirsutism]] | |||
*[[Insulin resistance syndrome]] <ref name="pmid20198556">{{cite journal| author=Klotz RK, Müller-Holzner E, Fessler S, Reimer DU, Zervomanolakis I, Seeber B et al.| title=Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature. | journal=Exp Clin Endocrinol Diabetes | year= 2010 | volume= 118 | issue= 5 | pages= 291-7 | pmid=20198556 | doi=10.1055/s-0029-1225351 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20198556 }} </ref> | |||
*[[Pegylated interferon alfa-2a|Interferon alfa]] | |||
*[[Isotretinoin]] | |||
*[[Lamotrigine]] | |||
*[[Leuprolide]] | |||
*[[Luteoma]] | |||
*[[Methyltestosterone]] | |||
*[[Miller-Dieker syndrome]] | |||
*[[Mycophenolate]] | |||
*[[Nodulosis-arthropathy-osteolysis syndrome]] | |||
*[[Olanzapine]] | |||
*[[Ovarian cancer]] | |||
*Ovarian hyperthecosis <ref name="pmid2062784">{{cite journal| author=Goldman JM, Kapadia LJ| title=Virilization in a postmenopausal woman due to ovarian stromal hyperthecosis. | journal=Postgrad Med J | year= 1991 | volume= 67 | issue= 785 | pages= 304-6 | pmid=2062784 | doi= | pmc=2399029 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2062784 }} </ref> | |||
*[[Ovarian tumor]] | |||
*[[Oxandrolone]] | |||
*[[Oxymetholone]] | |||
*[[Paroxetine]] | |||
*[[Phenytoin]] | |||
*[[Pituitary tumor]] | |||
*[[Polycystic ovary syndrome]] | |||
*[[Porphyria cutanea tarda]] | |||
*[[Prednisolone]] | |||
*[[Pregabalin]] | |||
*[[Progestin]] | |||
*[[Selegiline]] | |||
*[[Insulin resistance syndrome]] | |||
*[[Stein-Leventhal syndrome]] | |||
*[[Tacrolimus]] | |||
*[[Testicular tumor]] | |||
*[[Testosterone]] | |||
*[[Tiagabine]] | |||
*[[Trazodone]] | |||
*[[Turner syndrome]] | |||
*[[Valproic acid]] | |||
*[[Vasodilators]] | |||
*[[Venlafaxine]] | |||
*[[Zonisamide]] | |||
}} | }} | ||
Latest revision as of 15:13, 8 December 2020
Hirsutism Microchapters |
Diagnosis |
---|
Treatment |
Medical Therapy |
Case Studies |
Hirsutism causes On the Web |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: ; Ogheneochuko Ajari, MB.BS, MS [2] Rasam Hajiannasab M.D.[3]
Overview
The cause of hirsutism can be either an increased level of androgens (male hormones) or an oversensitivity of hair follicles to androgens, and the most common cause is polycystic ovary syndrome. Male hormones such as testosterone stimulate hair growth, increase size and intensify the pigmentation of hair. Other symptoms associated with a high level of male hormones include acne and deepening of the voice and increased muscle mass. Growing evidence implicates high circulating levels of insulin in women to the development of hirsutism. This theory is consistent with the observation that obese (and thus presumably insulin resistant hyperinsulinemic) women are at high risk of becoming hirsute. Further, treatments that lower insulin levels will lead to a reduction in hirsutism.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
- There are no known life threatening causes of hirsutism.
Common Causes
- Androgen secreting tumors [1]
- Congenital adrenal hyperplasia
- Cushing's syndrome
- Idiopathic hirsutism
- Polycystic ovary syndrome [2]
Causes by Organ System
Causes in Alphabetical Order
- 11β-hydroxylase deficiency
- 21-hydroxylase deficiency
- Achard-Thiers syndrome
- Acromegaly
- Adrenal adenoma
- Adrenal carcinoma
- Adrenal tumor
- Alpha-L-iduronidase deficiency
- Ambras syndrome
- Aripiprazole
- Arrhenoblastoma
- Bimatoprost
- Bupropion
- Carbamazepine
- Clonazepam
- Coffin-Siris syndrome
- Congenital adrenal hyperplasia
- Cornelia de Lange Syndrome
- Corticosteroids
- Cortisone reductase deficiency
- Cushing syndrome
- Cushing's disease
- Cyclosporine
- Danazol
- Dantrolene
- Dermatomyositis
- Desogestrel and ethinyl estradiol
- Dexamethasone
- Diazoxide
- Donepezil
- Estrogens
- Eszopiclone
- Ethosuximide
- Ethotoin
- Ethynodiol diacetate and ethinyl estradiol
- Fluoxetine
- Fluoxymesterone
- Gestrinone
- Hurler syndrome
- Hyperprolactinemia
- Hypertrichosis lanuginosa
- Hypothyroidism
- I-cell disease
- Idiopathic hirsutism
- Insulin resistance syndrome [1]
- Interferon alfa
- Isotretinoin
- Lamotrigine
- Leuprolide
- Luteoma
- Methyltestosterone
- Miller-Dieker syndrome
- Mycophenolate
- Nodulosis-arthropathy-osteolysis syndrome
- Olanzapine
- Ovarian cancer
- Ovarian hyperthecosis [3]
- Ovarian tumor
- Oxandrolone
- Oxymetholone
- Paroxetine
- Phenytoin
- Pituitary tumor
- Polycystic ovary syndrome
- Porphyria cutanea tarda
- Prednisolone
- Pregabalin
- Progestin
- Selegiline
- Insulin resistance syndrome
- Stein-Leventhal syndrome
- Tacrolimus
- Testicular tumor
- Testosterone
- Tiagabine
- Trazodone
- Turner syndrome
- Valproic acid
- Vasodilators
- Venlafaxine
- Zonisamide
References
- ↑ 1.0 1.1 Klotz RK, Müller-Holzner E, Fessler S, Reimer DU, Zervomanolakis I, Seeber B; et al. (2010). "Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature". Exp Clin Endocrinol Diabetes. 118 (5): 291–7. doi:10.1055/s-0029-1225351. PMID 20198556.
- ↑ Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR (2004). "Androgen excess in women: experience with over 1000 consecutive patients". J. Clin. Endocrinol. Metab. 89 (2): 453–62. doi:10.1210/jc.2003-031122. PMID 14764747.
- ↑ Goldman JM, Kapadia LJ (1991). "Virilization in a postmenopausal woman due to ovarian stromal hyperthecosis". Postgrad Med J. 67 (785): 304–6. PMC 2399029. PMID 2062784.